Oncotarget

Research Papers:

Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis

Chao-yuan Huang, Qian-yi Zhou, Yue Hu, Yi Wen, Zhen-wen Qiu, Man-guang Liang, Jun-ling Mo, Jian-hua Xu, Cong Sun, Feng-bin Liu and Xin-lin Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23459-23469. https://doi.org/10.18632/oncotarget.15589

Metrics: PDF 1049 views  |   HTML 1100 views  |   ?  


Abstract

Chao-yuan Huang1,*, Qian-yi Zhou1,*, Yue Hu2, Yi Wen1, Zhen-wen Qiu3, Man-guang Liang4, Jun-ling Mo4, Jian-hua Xu5, Cong Sun6, Feng-bin Liu3, Xin-lin Chen2

1The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China

2School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China

3The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

4The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China

5The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, China

6Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, China

*These authors contributed equally to this work

Correspondence to:

Feng-bin Liu, email: liufb163@163.com

Xin-lin Chen, email: chenxlsums@126.com

Keywords: hepatocyte growth factor, prognosis, marker, colorectal cancer, meta-analysis

Received: November 04, 2016     Accepted: February 12, 2017     Published: February 21, 2017

ABSTRACT

Hepatocyte growth factor (HGF) is a crucial factor associated with development, progression and metastasis of colorectal cancer (CRC). However, its prognostic value remains unclear. Thus studies referring to the correlation between HGF and CRC patients’ prognosis were included to explore the role of HGF in CRC. At last nine articles were included. The results showed that the over-expression of HGF was associated with a poor prognosis, presented through overall survival (OS, Hazard ratio (HR) = 2.50, 95% confidence interval (CI): 2.12–2.96) and disease-free survival (DFS, HR = 1.99, 95% CI: 1.59–2.50). Subgroup analysis indicated that no significant difference was found between the Asian countries (OS: HR = 2.37; DFS: HR = 2.02) and the non-Asian countries (OS: HR = 3.15; DFS: HR = 1.87), between the studies that used univariate analyses (OS: HR = 2.51; DFS: HR = 2.07) and those that used multivariate analyses (OS: HR = 2.65; DFS: HR = 1.78), and between metastatic CRC (OS: HR = 2.26; DFS: HR = 2.06) and stage I-IV CRC (OS: HR = 3.08; DFS: HR = 0.70). Our meta-analysis has shown that the over-expression of HGF is valuable in CRC prognosis evaluation. This conclusion should be further confirmed by large-sample cohort studies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15589